A previous study identified that an approximately 2900-bp deletion polymorphism of BIM could deregulate the proapoptotic function of the BIM protein, consequently inducing primary resistance in chronic myelogenous leukemia (CML) and NSCLC cell lines, and could predict a poor response to the EGFR-TKIs treatment [24]. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.